Illumina, Inc. (NASDAQ:ILMN) Receives $140.90 Average Price Target from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average recommendation of “Hold” by the twenty-one ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $140.65.

Several research firms recently weighed in on ILMN. Guggenheim cut their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Citigroup dropped their price target on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Finally, TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and reduced their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently added to or reduced their stakes in the company. Capital World Investors increased its holdings in shares of Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock worth $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. grew its position in Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock worth $255,586,000 after acquiring an additional 1,909,118 shares during the last quarter. Norges Bank acquired a new stake in Illumina during the 4th quarter valued at $228,714,000. Bessemer Group Inc. boosted its stake in Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock worth $180,152,000 after purchasing an additional 1,344,038 shares in the last quarter. Finally, WCM Investment Management LLC increased its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 1.0 %

Shares of ILMN stock opened at $73.45 on Friday. Illumina has a 12 month low of $69.55 and a 12 month high of $156.66. The company has a market cap of $11.63 billion, a PE ratio of -9.56, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $95.52 and its two-hundred day moving average is $124.59.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts predict that Illumina will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.